3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Uterine Cervical Neoplasms
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Neoplasms
1
Melanoma
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Adenocarcinoma
1
Carcinoma, Hepatocellular
1
Adenomatous Polyposis Coli
1
Interventions
Amifostine
4
Cisplatin
3
Voriconazole
2
Radiotherapy
2
Paclitaxel
2
Methotrexate
2
Drug Therapy
2
selinexor
1
sargramostim
1
pazopanib
1
lometrexol
1
icotinib
1
glucarpidase
1
camrelizumab
1
bismuth tripotassium dicitrate
1
apatinib
1
Telbivudine
1
Surgical Procedures, Operative
1
Pregabalin
1
Pharmaceutical Preparations
1
Ofloxacin
1
Nivolumab
1
Metronidazole
1
Levofloxacin
1
Imatinib Mesylate
1
Hyperthermic Intraperitoneal Chemotherapy
1
Gefitinib
1
Folic Acid
1
Etoposide
1
Esomeprazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Drug-Related Side Effects and Adverse Reactions
×
Pharmaceutical Preparations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled